Executive Summary
The PTAB instituted an inter partes review of Inari Medical’s 11,554,005 patent covering intravascular embolism treatment devices after finding Imperative Care’s likelihood of success on at least one claim. The decision centers on claim constructions of the “filament” element and obviousness over multiple prior‑art references.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Imperative Care, Inc. vs Inari Medical, Inc. et al. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Tesla, Inc.vsPerceptive Automata LLC
The USPTO granted institution for IPR2025-01574 after determining the petitioner had a reasonable likelihood of prevailing on at least one challenged claim. This decision allows the case to proceed to merits review.
Sportradar AG et al.vsSportsCastr Inc. (d/b/a PANDA Interactive)
Sportradar has filed an IPR petition challenging 18 claims of SportsCastr’s live‑streaming patent, arguing obviousness over Ellis, Herzog, Spivey and Abulikemu and asserting that the examiner failed to consider key prior art.
PacifiCorp et al.vsMES, Inc.
BirchTech Corp. seeks Director Review to overturn the PTAB’s decision to institute an IPR against its mercury‑control patent, arguing MDL efficiency and a misapplied privity analysis under §315(b).
Imperative Care, Inc.vsInari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s 11,697,012 patent covering hemostasis valves after finding Imperative Care’s petition shows a reasonable likelihood of success on at least one claim.
Samsung Electronics Co., Ltd. et al.vsOura Health Oy et al.
The PTAB issued a Final Written Decision rejecting all grounds of obviousness (35 U.S.C. § 103) against the smart ring patent. The Board upheld the validity of the claims, finding that the combination of prior art references required non-obvious structural overhauls and lacked proper nexus to the claimed invention.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.